Statera utilizes its patented Spatiotemporally Tuned Particles (STP) technology to achieve optimized, sequential delivery of antigen-specific immunotherapies for autoimmune diseases, significantly enhancing bioavailability while reducing side effects and dosage frequency. This approach addresses the limitations of conventional immunosuppressants, which often lead to increased infection risk and adverse effects in patients.
Funding
$440K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current immunosuppressant treatments for autoimmune diseases often have limitations, including increased risk of infection and other adverse side effects. Conventional methods may also suffer from suboptimal bioavailability and require frequent dosing.
Solution
Statera is developing antigen-specific immunotherapies for autoimmune diseases using its proprietary Spatiotemporally Tuned Particles (STP) technology. This approach aims to optimize the sequential delivery of targeted therapies, enhancing bioavailability and reducing the frequency of required dosages. By precisely controlling the timing and location of drug release, Statera's technology seeks to minimize off-target effects and improve the overall therapeutic window for patients. The STP platform is designed to address the shortcomings of traditional immunosuppressants by offering a more targeted and controlled method of drug delivery.
Target Audience
The primary target audience includes individuals suffering from autoimmune diseases and the healthcare providers who treat them.
Features
- Spatiotemporally Tuned Particles (STP) technology for controlled drug release
- Optimized sequential delivery of antigen-specific immunotherapies
- Enhanced bioavailability of therapeutic agents
- Reduced dosage frequency compared to conventional treatments
- Targeted delivery to minimize off-target effects